DongKoo Bio & Pharma Co., Ltd.: debt-to-equity, ROE and more
KOSDAQ, Legal name DongKoo Bio & Pharma Co., Ltd.
Latest figures are the FY2025 consolidated summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 121.1%
- Equity ratio
- 45.2%
- ROE
- 33.0%
- Op. margin
- 3.8%
- Rev. growth
- -2.6%
- Interest coverage
- n/a
Condition flags
- Operating profit for 5 straight years.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
| Fiscal year | Cash dividend per share | Payout ratio |
|---|---|---|
| 2025 | ₩120 | 6.5% |
| 2024 | ₩120 | 160.1% |
| 2023 | ₩120 | 28.1% |
Cash dividends for 3 straight years (only the 3 years OpenDART returns).
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 consolidated | 54.6% | 64.7% | 9.3% | 5.2% | n/a |
| FY2022 consolidated | 68.5% | 59.3% | 6.5% | 8.7% | 25.7% |
| FY2023 consolidated | 73.0% | 57.8% | 10.7% | 6.8% | 10.6% |
| FY2024 consolidated | 131.5% | 43.2% | 1.9% | 5.1% | 15.6% |
| FY2025 consolidated | 121.1% | 45.2% | 33.0% | 3.8% | -2.6% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩155.1B | ₩195.0B | ₩215.7B | ₩249.3B | ₩242.7B |
| Operating profit | ₩8.1B | ₩17.0B | ₩14.6B | ₩12.7B | ₩9.2B |
| Pre-tax income | ₩11.3B | ₩7.9B | ₩14.7B | ₩3.8B | ₩61.4B |
| Net income | ₩9.3B | ₩6.6B | ₩11.8B | ₩2.0B | ₩50.2B |
| Total assets | ₩154.8B | ₩172.1B | ₩191.1B | ₩244.1B | ₩336.3B |
| Total liabilities | ₩54.7B | ₩70.0B | ₩80.7B | ₩138.6B | ₩184.2B |
| Total equity | ₩100.1B | ₩102.1B | ₩110.4B | ₩105.4B | ₩152.2B |
| Paid-in capital | ₩14.2B | ₩14.2B | ₩14.2B | ₩14.2B | ₩14.2B |
| Debt/equity (source value) | 54.6% | 68.5% | 73.0% | 131.5% | 121.1% |
Company outline (FSC)
- Market
- KOSDAQ
- Fiscal year end
- Dec
- Founded
- 1983-07-01
- Listed
- 18/02/13
- Employees
- 440
- Auditor
- 삼정회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 1101110352156
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 동구바이오제약Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.